A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma

Oncologist

Volumn 18, Issue 4, 2013, Pages 379-380

  Rimassa, Lorenza ^a   Pressiani, Tiziana ^a   Boni, Corrado ^b   Carnaghi, Carlo ^a   Rota Caremoli, Elena ^c   Fagiuoli, Stefano ^c   Foa, Paolo ^d   Salvagni, Stefania ^e   Cortesi, Enrico ^f   Chiara Tronconi, Maria ^a   Personeni, Nicola ^a   Bozzarelli, Silvia ^a   Chiara Banzi, Maria ^b   Fanello, Silvia ^b   Romano Lutman, Fabio ^a   Giordano, Laura ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b IRCCS   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; WEIGHT REDUCTION;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84877029405     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0221     Document Type: Article

References (0)